Status: Recruiting
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Participants needed: 895
Trial details
Phase: Phase 3Age: 18-99Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Jun 29, 2026Locations: 284
Eligibility criteria
Adult females (pre-/peri-/ and post-menopausal), and adult males. [+8]
History of another primary malignancy except for malignancy treated with curativ... [+12]